PM Modi Unveils Advanced Level Research Centre to Strengthen Pharma Sector

ALRC is expected to contribute to pharmaceutical standardization and the availability of high-quality and safe medicines at affordable costs in India.

In a step towards advancing pharmaceutical research and development in India, Prime Minister Narendra Modi virtually inaugurated the state-of-the-art Advanced Level Research Centre (ALRC) of the Indian Pharmacopoeia Commission (IPC).

The event marked the establishment of a cutting-edge laboratory facility dedicated to enhancing standards and research in the pharmaceutical sector.

The Prime Minister virtually inaugurated the ALRC at IPC in Ghaziabad from Rajkot, Gujarat. The event was attended by key dignitaries, including Dr Mansukh Mandaviya, Union Minister of Health and Family Welfare and Chemicals and Fertilizers; Prof S P Singh Baghel, Union Minister of State of Health and Family Welfare; and Dr Bharati Pravin Pawar, Union Minister of State of Health and Family Welfare and Ministry of Tribal Affairs.

General (Dr) V K Singh (Retd), Union Minister of State for Civil Aviation, Road Transport, and Highways was physically present at IPC, Ghaziabad.

Built at a cost of INR 49 Cr, the ALRC boasts modern infrastructure and facilities designed to support high-quality research and training programs.

This development reflects a commitment to elevating Indian pharmaceuticals to a higher standard on the global stage, contributing to the growth of the country's pharmaceutical industry.

Prime Minister Modi acknowledged the efforts of the Drugs Controller General of India (DCGI), Dr Rajeev Raghuvanshi, and his team at IPC for their dedication to realizing this milestone.

The ALRC, equipped with cutting-edge technology, is poised to play a pivotal role in advancing pharmaceutical research and development in India.

Significance of ALRC

The ALRC holds strategic importance as a hub for cutting-edge research, innovation, and training in pharmacopeia standards-setting, pharmacovigilance, and related areas.

It is expected to contribute to solving critical challenges and obstacles in pharmaceutical standardization, ensuring the availability of high-quality and safe medicines at affordable costs in India.

Speaking on the occasion, General (Dr) V K Singh congratulated IPC on the completion and inauguration of ALRC, which will serve as a testament to IPC's commitment to advancing pharmaceutical research and development in India.

"ALRC will serve the nation as a hub for cutting-edge research, innovation, and training in the field of pharmacopoeia standards-setting, pharmacovigilance, and other allied areas," he added.

The ALRC aligns with India's broader vision of enhancing its global standing in the pharmaceutical sector. By investing in state-of-the-art research facilities and infrastructure, the country aims to set higher standards and contribute to the development of innovative pharmaceutical solutions.

Future Prospects

The ALRC is poised to become a catalyst for pioneering research, fostering innovation, and providing valuable training in the pharmaceutical domain.

As India aims to achieve new milestones in pharmaceutical development, the ALRC is expected to play a central role in driving advancements and ensuring the nation's pharmaceutical industry remains at the forefront of global innovation.

The commitment to cutting-edge facilities and research initiatives underscores India's determination to lead in the global pharmaceutical landscape, contributing to the availability of safe and affordable medicines.

In another recent development, PM Modi inaugurated five All India Institutes of Medical Sciences (AIIMS) across various states and initiated over 200 healthcare infrastructure projects, collectively valued at over INR 11,700 Cr, in a step towards bolstering India's healthcare infrastructure.

The newly inaugurated AIIMS facilities are located in Rajkot (Gujarat), Bathinda (Punjab), Raebareli (Uttar Pradesh), Kalyani (West Bengal), and Mangalagiri (Andhra Pradesh), symbolizing a concerted effort to enhance tertiary healthcare services across the nation.